We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI-Driven Blood Test to Revolutionize Diagnosis of Long COVID in Children

By LabMedica International staff writers
Posted on 29 Jan 2025

Long COVID affects about 0. More...

5% of pediatric patients exposed to SARS-CoV-2. Also known as post-COVID or post-acute sequelae of SARS-CoV-2, this condition is characterized by persistent symptoms that appear after the viral infection and last for at least 8-12 weeks, significantly impacting daily life. Long COVID has been observed across all age groups, with children over the age of 10 being particularly affected in terms of severity. While proteomic studies have highlighted a pro-inflammatory signature and thrombo-inflammation in adults with long COVID, similar findings had not been documented in the pediatric population. Now, a new method can accurately diagnose long COVID in children using a blood sample and artificial intelligence (AI).

In a study led by researchers at Università Cattolica del Sacro Cuore (UCSC, Milan, Italy) and associated institutions, an AI tool was found to effectively detect the molecular signature of long COVID in plasma samples from pediatric patients, with an accuracy rate of 93%. For their research, the team performed a detailed protein analysis on blood plasma from children under 19 years of age, comparing those with long COVID to control groups including children with acute COVID-19, MIS-C, and healthy controls. Children were classified as having long COVID if they experienced persistent symptoms for at least 8 weeks after the initial infection, which negatively impacted their daily activities and could not be attributed to other causes. The study included 112 children, with 34 meeting the clinical criteria for long COVID, 32 with acute SARS-CoV-2 infection, 27 with MIS-C, and 19 healthy controls.

The study, published in the journal Pediatric Research, showed that children with long COVID showed higher expression of a specific set of pro-inflammatory and pro-angiogenic chemokines (CXCL11, CXCL1, CXCL5, CXCL6, CXCL8, TNFSF11, OSM, STAMBP1a) compared to controls. Using a machine learning model based on this proteomic profile, researchers identified long COVID with an accuracy of 93%, a specificity of 86%, and a sensitivity of 97%. The findings indicate that pediatric long COVID is characterized by an increased blood protein signature associated with ongoing general and endothelial inflammation, similar to what has been observed in adults. This study is the first to document the pro-inflammatory profile in children with long COVID, and the results may contribute to the development of future diagnostic tests.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gastrointestinal Panel
Xpert® GI Panel
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.